Cancer Clinical Trial
— STREAMOfficial title:
Web-based Stress Management for Newly Diagnosed Cancer Patients (STREAM-1): A Randomized, Wait-list Controlled Intervention Study
Verified date | May 2017 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Many cancer patients experience their illness as substantial psychological burden. About
half of the cancer patients suffer from severe stress symptoms and around one third of the
patients fulfill the criteria for a clinically relevant psychological disorder (mainly
anxiety disorder and/or major depression). Studies show, that a high level of distress in
cancer patients is associated with more side effects of and a reduced compliance for
oncological treatment.
Today, the efficacy of psycho-oncological interventions is well studied and proven. Besides
the reduction of levels of anxiety, distress and depression, psycho-oncological support
facilitates dealing with physical complaints and increases quality of life. Yet,
psycho-oncological support is rarely utilized by male patients and insufficiently accessible
for many patients (i.a. lack of supply in the respective area, cost issues).
The internet overcomes some of these barriers, as it can be used independently of time and
location. Internet-based therapies are therefore a growing field of interest in research and
there is evidence for treatment efficacy for several psychological disorders. Moreover
effect sizes of traditional face-to-face and interactive web-based interventions are
comparable. However, web-based interventions for cancer patients are still scarce. The
present research project therefore develops a comprehensive stress management program
accessible for a vast number of cancer patients. The study targets primarily to evaluate the
feasibility of the program (technical, organizational feasibility, accessibility). In
addition, the preliminary efficacy of the program will be analyzed in order to adapt future
programs for specific patient groups.
Status | Completed |
Enrollment | 129 |
Est. completion date | March 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with any kind of newly diagnosed cancer undergoing first treatment (including radiotherapy, hormonal treatment, targeted therapies, chemotherapy or combined-modality treatment) regardless of the setting (adjuvant treatment, curative treatment, palliative first-line treatment) - Patients with newly diagnosed relapse of cancer, who had received prior curatively-intended treatment - Inclusion is allowed immediately prior to or within 12 weeks of the start of treatment - Patients must have cytologically or histologically proven diagnosis of malignant disease (either at diagnosis or at relapse) - Prior treatment -including chemotherapy- for a different, prior malignant tumor is allowed - Concomitant participation in an experimental therapeutic drug trial is allowed - Age >18 years - Command of the German language - Internet access and basic computer skills - Life expectancy of >6 months Exclusion Criteria: - Patients undergoing palliative second- or further line chemotherapy treatment - Patients treated with surgery only - Patients participating in a concomitant psychological intervention trial |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Basel | Basel |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland | Swiss Cancer Research, Swiss National Science Foundation |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dropout rate during the internet-based recruitment procedure | Measures assessed at time point of recruitment | ||
Primary | Characteristics (Sociodemographic and medical history; i.e. age, gender, education, cancer diagnosis and cancer treatment) of the population willing to participate in an online stress management program shortly after diagnosis of cancer | Measures assessed at time point of recruitment | ||
Primary | Number of participants who completed at least 6 out of 8 modules, i.e. 75 % of each module | participants will be followed for the duration of the intervention, an expected average of 8 weeks | ||
Primary | Working Alliance scores on the Working Alliance (WAI) Questionnaire | participants will be followed for the duration of the intervention, an expected average of 8 weeks | ||
Primary | Usability scores on the System Usability Scale (SUS) | participants will be followed for the duration of the intervention, an expected average of 8 weeks | ||
Primary | Client satisfaction on the Client Satisfaction Questionnaire-8 (CSQ-8) | German Version of the Client Satisfaction Questionnaire: Fragebogen zur Messung der Patientenzufriedenheit (ZUF-8) will be used | Measures assessed after 8 weeks | |
Secondary | Psychological distress on the Distress Thermometer (visual analogue scale) | Change measures (e.g., "baseline, 8 weeks") | ||
Secondary | Anxiety and Depression scores on the Hospital Anxiety and Depression Scale (HADS) | Change measures (e.g., "baseline, 8 weeks") | ||
Secondary | Quality of life and fatigue scores on the Functional Assessment in Cancer Therapy-Fatigue (FACT-F) | hange measures (e.g., "baseline, 8 weeks") | ||
Secondary | Avoidance and psychological inflexibility scores on the Acceptance and Action questionnaire (AAQ) | German Version of the Acceptance and Action questionnaire: Fragebogen zur Akzeptanz und Handeln (FAH II) will be used | ange measures (e.g., "baseline, 8 weeks") |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|